MGC Pharmaceuticals Ltd.

Appointment of UK Lead Broker and Change of Company Secretary

01 March 2023

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') is pleased to announce the appointment of UK based Peterhouse Capital as the Company's lead broker on the LSE, with immediate effect, replacing Turner Pope. This appointment is part of the Company's UK focused corporate strategy with respect to future equity capital market financings and corporate opportunities.

The Company also advises that Mr David Lim, MGC Pharma's Company Secretary, has retired from the position. Mr Lim has overseen the transition of the Company's corporate compliance structure to one that is significantly more organised and well positioned for the future.

Mr Lim is replaced as MGC Pharma's Company Secretary by Messrs Rowan Harland and Arron Canicais of SmallCap Corporate Pty Ltd, a Perth based corporate advisory firm, who have been appointed Joint Company Secretaries effective today.

MGC Pharma's non-executive chairman, Mr Brett Mitchell, commented "The board is very pleased to welcome the appointment of Peterhouse Capital as lead broker for the LSE to play a key role in the company's future funding strategies and corporate opportunities. In addition, we would also like to thank Mr David Lim for his dedication and commitment to the Company, and the board wishes him every success with his next venture."

--Ends--

Authorised for release by the board of directors, for further information please contact:

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development. 

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities. 

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma